Your browser is no longer supported. Please, upgrade your browser.
ORGO Organogenesis Holdings Inc. daily Stock Chart
Organogenesis Holdings Inc.
Index- P/E20.30 EPS (ttm)0.39 Insider Own91.81% Shs Outstand93.61M Perf Week-21.72%
Market Cap748.88M Forward P/E- EPS next Y- Insider Trans- Shs Float62.71M Perf Month-94.16%
Income3.90M PEG- EPS next Q- Inst Own28.60% Short Float0.01% Perf Quarter-20.71%
Sales182.99M P/S4.09 EPS this Y- Inst Trans-7.04% Short Ratio0.08 Perf Half Y-20.00%
Book/sh30.78 P/B0.26 EPS next Y- ROA1.20% Target Price- Perf Year-18.62%
Cash/sh0.00 P/C- EPS next 5Y- ROE1.30% 52W Range7.87 - 310.90 Perf YTD-21.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-97.43% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low1.65% ATR16.38
Employees4 Current Ratio0.00 Sales Q/Q-1.30% Oper. Margin- RSI (14)40.71 Volatility7.82% 27.07%
OptionableNo Debt/Eq0.00 EPS Q/Q265.50% Profit Margin- Rel Volume0.74 Prev Close8.00
ShortableNo LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume48.75K Price8.00
Recom- SMA20-49.96% SMA50-63.76% SMA200-38.53% Volume36,195 Change0.00%
Jan-24-19 10:00AM  Organogenesis to Sponsor Jan. 30 Webinar, Chronic Wounds and Biofilms: Advancing Assessment and Treatment, Featuring Dr. Gregory Schultz GlobeNewswire -8.13%
Jan-07-19 05:54PM  Organogenesis Holdings Inc. Receives Positive Nasdaq Listing Determination PR Newswire
04:15PM  Nasdaq Scheduled Resumption in Organogenesis Holdings Inc. GlobeNewswire
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company was founded in 1985 and is headquartered in Canton, Massachusetts.